MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics Long-Term Debt 2011-2026 | NLTX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 K | 66 K | 67 K | 11.3 K | - | - | - | - | - | - | 2.04 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.04 M | 11.3 K | 449 K |
Quarterly Long-Term Debt Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 K | 9 K | 17 K | 26 K | 39 K | 53 K | - | 65 K | 5 K | 6 K | 7 K | 233 K | 9 K | 10 K | 66 K | 67 K | 68 K | 68 K | 122 K | 108 K | 108 K | 108 K | 108 K | 146 K | 146 K | 146 K | 146 K | 6 K | 6 K | 6 K | 6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 233 K | 5 K | 63.9 K |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
295 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
4.27 M | $ 2.54 | 1.6 % | $ 1.33 B | Canada |
 |
Assertio Holdings
ASRT
|
39.1 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
146 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
5 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
250 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
446 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
39.9 K | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
3.6 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
8.29 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
1.69 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
6.53 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
1.23 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
2.92 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
221 M | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
18 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
2.4 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
120 K | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
1.47 M | - | -0.21 % | $ 98 M | USA |